DDrare: Database of Drug Development for Rare Diseases

145. ウエスト症候群
［臨床試験数：39，薬物数：50（DrugBank：13），標的遺伝子数：27，標的パスウェイ数：24］

Searched query = "West syndrome", "Infantile spasm"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18 FDG; ACTH; Acetate; Adrenocorticotropin hormone; CANNABIDIOL; CBD; Cannabidiol; Cannabidiol (CBD); Cannabidiol Oral Solution; Combination therapy with vigabatrin and prednisolone; Cosyntropin; Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin; Cosyntropin Injectable Suspension, 1 mg/mL; Decortin H; Fenfluramine; GWP42003-P; Ganaxolone; Intravenous Methylprednisolone; JBPOS0101; M071754; Melatonin; Methylprednisolone; Modified Atkins diet; Null; Oral Pednisolone; Oral prednisolone; Other: modified Atkins diet; Prednisolone; Pyridoxine; Pyridoxine plus prednisolone; Radiprodil; SABRIL; SABRIL SACHETS; SOLUBLE PREDNISOLONE TABLETS; SPT3162; SYNACTHEN DEPOT; Sabril; Sabril granules for oral use; Sabrilex; Sabril®; Synacthen Depot; Tetracosactide; Tetracosactide Acetate; UCB3491; VGB-ST; VGB-ST soluble tablets; VIGABATRIN; Vigabatrin; Vigabatrin Tablets; Vigabatrin: Vigabatrin new ST formulation then Sabril®

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03347526 (ClinicalTrials.gov)	April 19, 2018	15/11/2017	A Novel Approach to Infantile Spasms	A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy	Infantile Spasm	Drug: Cosyntropin Injectable Suspension, 1 mg/mL;Drug: Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin;Drug: Vigabatrin	University of Colorado, Denver	Pediatric Epilepsy Research Foundation;West Therapuetics, Inc	Suspended	2 Months	2 Years	All	394	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03347526
(ClinicalTrials.gov)

April 19, 2018

15/11/2017

A Novel Approach to Infantile Spasms

A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy

Infantile Spasm

Drug: Cosyntropin Injectable Suspension, 1 mg/mL;Drug: Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin;Drug: Vigabatrin

University of Colorado, Denver

Pediatric Epilepsy Research Foundation;West Therapuetics, Inc

Suspended

2 Months

2 Years

All

394

Phase 3

United States